Compare WSR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | CMPX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.9M | 927.5M |
| IPO Year | 2002 | 2020 |
| Metric | WSR | CMPX |
|---|---|---|
| Price | $18.97 | $2.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $19.00 | $14.57 |
| AVG Volume (30 Days) | 366.9K | ★ 12.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 31.94 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $160,859,000.00 | N/A |
| Revenue This Year | $2.77 | N/A |
| Revenue Next Year | $4.21 | $934.41 |
| P/E Ratio | $237.13 | ★ N/A |
| Revenue Growth | ★ 4.26 | N/A |
| 52 Week Low | $11.43 | $1.61 |
| 52 Week High | $19.01 | $6.88 |
| Indicator | WSR | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 76.91 | 34.36 |
| Support Level | $18.90 | $1.61 |
| Resistance Level | $19.00 | $3.54 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.09 | 0.13 |
| Stochastic Oscillator | 16.66 | 78.75 |
Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.